Navigation Links
Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
Date:3/10/2011

A; the therapeutic and commercial value of Contrave; Orexigen's ability to attract and retain key personnel; Orexigen's ability to maintain sufficient capital; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in Orexigen's Quarterly Report on Form 10-Q, which we intend to file with the Securities Exchange Commission this week and will be available from the SEC's website (www.sec.gov) and on our website (www.orexigen.com) under the heading "Investor Relations." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
4. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
5. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
6. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
7. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
8. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
9. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
10. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
11. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... -- Although colonoscopy exams prevent many colon cancer deaths ... for detecting colorectal cancers 2 , the procedure is ... EndoChoice ® Inc. today unveiled research that shows ... of this procedure and greatly reduces the number of ... clinical trial results and featuring the Fuse system that ...
(Date:5/18/2013)... , May 18, 2013 The Open ... , Occupy Psychiatry , and leading ... care, announces a social media campaign showcasing video ... psychiatric model, which focuses on pathology and illness ... with the American Psychiatric Association,s (APA) rollout of ...
(Date:5/18/2013)... , May 18, 2013 Faruqi ... firm, is investigating potential securities fraud at AVEO ... (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... and its executives violated federal securities laws by ... Company,s Phase III drug trials for Tivopath (tivozanib) ...
Breaking Medicine Technology:New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2
... , , , GREENSBORO, N.C., Dec. 23 ... for four users who allege kidney damage due to the ... intestines in preparation for a colonoscopy. (Holshouser et al ... actions are against two Morrisville, N.C., pharmaceutical companies, Salix Pharmaceuticals, ...
... , , , , IRVINE, Calif., ... of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low Perfusion pulse oximetry, ... 28th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis ... p.m. Pacific Time. A live audiocast of the presentation will ...
Cached Medicine Technology:Suits Commenced Against Maker of Prescription Cleansing Drug 2Masimo to Present at the 28th Annual J.P. Morgan Healthcare Conference 2Masimo to Present at the 28th Annual J.P. Morgan Healthcare Conference 3
(Date:5/18/2013)... of coffee is associated with a reduced risk ... disease, Mayo Clinic research shows. The findings were ... conference in Orlando, Fla. , PSC is ... results in inflammation and subsequent fibrosis that can ... and biliary cancer. , "While rare, PSC has ...
(Date:5/18/2013)... Utah (PRWEB) May 18, 2013 ... on insurance agents’ role in Marketplaces . ... to traditional employer sponsored health benefits, is the ... and health reimbursement arrangements . , ... Health and Human Services (HHS) recently released a ...
(Date:5/18/2013)... The “World Healthcare IT Market: Trends & ... market drivers, restraints, and opportunities in North America, Europe, ... 89 market data tables , ... IT Market" , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , ... The global healthcare IT market is expected to grow ...
(Date:5/18/2013)... 18, 2013 As metal-on-metal hip ... the country, Bernstein Liebhard LLP notes that a new ... suffer tissue damage before they experience any pain from ... Science Daily will appear in the Journal of Bone ... MRI screens of their hips. The researchers found ...
(Date:5/18/2013)... “Sleep Apnea Diagnostic & Therapeutic Devices Market [Polysomnographs, Respiratory ... Appliances, Nasal EPAP, Neurostimulation] Global End-user Analysis, Competitive Landscape ... market drivers, restraints, and opportunities in North America, Europe, ... 147 market data tables ... 318 pagesand in-depth TOC of “Sleep Apnea Diagnostic ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3
... , FRIDAY, Feb. 18 (HealthDay News) -- Patients with ... radiation treatments have a much lower long-term survival rate than ... the study of patients with squamous cell carcinoma of the ... to smoke were still alive five years after treatment, compared ...
... Scientists at the Children,s Center for Cancer and Blood ... Los Angeles today announced a breakthrough discovery in understanding ... a protein called CD19-ligand (CD19-L) located on the surface ... and destruction of leukemia cells by the immune system. ...
... 18 (HealthDay News) -- Speaking more than one language may ... that bilingual speakers outperform people who speak only one language ... irrelevant information to focus on important information. This means bilingual ... than one project at a time, said Judith Kroll, ...
... bigger role in the American health care system, argued ... conference of the American Association for the Advancement of ... health care costs depend on the policy context in ... Meltzer, Associate Professor of Medicine, in his presentation, "Policies ...
... leading lung cancer screening researchers, doctors and advocates. ... Early Lung Cancer Action Program (I-ELCAP) Screening Conferences. ... International Early Lung Cancer Action Program (I-ELCAP) and ... International Lung Cancer Consortium (ILCCO). This meeting ...
... (Feb 18, 2011) James C. Wittig, M.D., chief ... the John Theurer Cancer Center at Hackensack University Medical ... approaches to orthopedic oncology at the upcoming American Academy ... inventing some of the most-used best practices in limb-sparing ...
Cached Medicine News:Health News:Smoking During Head & Neck Cancer Therapy Tied to Poor Outcome 2Health News:Scientists bioengineer a protein to fight leukemia 2Health News:Cost-effectiveness research needs to be considered in developing new medical technology 2Health News:World's largest lung cancer screening conference to address benefits of CT scans 2Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 2Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 3Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 4Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 5Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 6Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 7
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... The AccuDrain System is a panel mounted system ... many critical needs of the heath care professional ... drainage system available with a dual action lever ... quickly attached to an IV pole. Similarly, ...
Medicine Products: